Matches in SemOpenAlex for { <https://semopenalex.org/work/W4220966716> ?p ?o ?g. }
- W4220966716 endingPage "715" @default.
- W4220966716 startingPage "715" @default.
- W4220966716 abstract "Due to its role in lipid biosynthesis, choline kinase α1 (CKα1) is an interesting target for the development of new antitumor agents. In this work, we present a series of 41 compounds designed based on the well-known and successful strategy of introducing thienopyridine and pyrimidine as bioisosteres of other heterocycles in active antitumor compounds. Notwithstanding the fact that some of these compounds do not show significant enzymatic inhibition, others, in contrast, feature substantially improved enzymatic and antiproliferative inhibition values. This is also confirmed by docking analysis, whereby compounds with longer linkers and thienopyrimidine cationic head have been identified as the most compelling. Among the best compounds is Ff-35, which inhibits the growth of different tumor cells at submicromolar concentrations. Moreover, Ff-35 is more potent in inhibiting CKα1 than other previous biscationic derivatives. Treatment of A549, Hela, and MDA-MB-231 cells with Ff-35 results in their arrest at the G1 phase of the cell cycle. Furthermore, the compound induces cellular apoptosis in a concentration-dependent manner. Altogether, these findings indicate that Ff-35 is a promising new chemotherapeutic agent with encouraging preclinical potential." @default.
- W4220966716 created "2022-04-03" @default.
- W4220966716 creator A5006370304 @default.
- W4220966716 creator A5007383910 @default.
- W4220966716 creator A5011996566 @default.
- W4220966716 creator A5015800627 @default.
- W4220966716 creator A5026452263 @default.
- W4220966716 creator A5041304639 @default.
- W4220966716 creator A5041904608 @default.
- W4220966716 creator A5049706456 @default.
- W4220966716 creator A5055861536 @default.
- W4220966716 creator A5063620408 @default.
- W4220966716 creator A5076487393 @default.
- W4220966716 creator A5077010876 @default.
- W4220966716 creator A5088496504 @default.
- W4220966716 creator A5089143700 @default.
- W4220966716 date "2022-03-27" @default.
- W4220966716 modified "2023-09-30" @default.
- W4220966716 title "Biological Evaluation of New Thienopyridinium and Thienopyrimidinium Derivatives as Human Choline Kinase Inhibitors" @default.
- W4220966716 cites W1599985274 @default.
- W4220966716 cites W1970020398 @default.
- W4220966716 cites W1973847879 @default.
- W4220966716 cites W1985588649 @default.
- W4220966716 cites W1986094949 @default.
- W4220966716 cites W2000815209 @default.
- W4220966716 cites W2003102414 @default.
- W4220966716 cites W2014162759 @default.
- W4220966716 cites W2043509228 @default.
- W4220966716 cites W2045851135 @default.
- W4220966716 cites W2046996322 @default.
- W4220966716 cites W2055614532 @default.
- W4220966716 cites W2066207556 @default.
- W4220966716 cites W2066273100 @default.
- W4220966716 cites W2083166156 @default.
- W4220966716 cites W2085309285 @default.
- W4220966716 cites W2106383417 @default.
- W4220966716 cites W2113364934 @default.
- W4220966716 cites W2116166589 @default.
- W4220966716 cites W2126361053 @default.
- W4220966716 cites W2142268071 @default.
- W4220966716 cites W2150974219 @default.
- W4220966716 cites W2164703295 @default.
- W4220966716 cites W2173416403 @default.
- W4220966716 cites W2326487378 @default.
- W4220966716 cites W2328491406 @default.
- W4220966716 cites W2396930286 @default.
- W4220966716 cites W2403922329 @default.
- W4220966716 cites W2593436234 @default.
- W4220966716 cites W2786249664 @default.
- W4220966716 cites W2827544681 @default.
- W4220966716 cites W2896042812 @default.
- W4220966716 cites W2912378715 @default.
- W4220966716 cites W2923867048 @default.
- W4220966716 cites W2968794930 @default.
- W4220966716 cites W2989894171 @default.
- W4220966716 cites W3083190354 @default.
- W4220966716 cites W3196492321 @default.
- W4220966716 cites W3210235236 @default.
- W4220966716 cites W4241534679 @default.
- W4220966716 doi "https://doi.org/10.3390/pharmaceutics14040715" @default.
- W4220966716 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35456549" @default.
- W4220966716 hasPublicationYear "2022" @default.
- W4220966716 type Work @default.
- W4220966716 citedByCount "2" @default.
- W4220966716 countsByYear W42209667162023 @default.
- W4220966716 crossrefType "journal-article" @default.
- W4220966716 hasAuthorship W4220966716A5006370304 @default.
- W4220966716 hasAuthorship W4220966716A5007383910 @default.
- W4220966716 hasAuthorship W4220966716A5011996566 @default.
- W4220966716 hasAuthorship W4220966716A5015800627 @default.
- W4220966716 hasAuthorship W4220966716A5026452263 @default.
- W4220966716 hasAuthorship W4220966716A5041304639 @default.
- W4220966716 hasAuthorship W4220966716A5041904608 @default.
- W4220966716 hasAuthorship W4220966716A5049706456 @default.
- W4220966716 hasAuthorship W4220966716A5055861536 @default.
- W4220966716 hasAuthorship W4220966716A5063620408 @default.
- W4220966716 hasAuthorship W4220966716A5076487393 @default.
- W4220966716 hasAuthorship W4220966716A5077010876 @default.
- W4220966716 hasAuthorship W4220966716A5088496504 @default.
- W4220966716 hasAuthorship W4220966716A5089143700 @default.
- W4220966716 hasBestOaLocation W42209667161 @default.
- W4220966716 hasConcept C1491633281 @default.
- W4220966716 hasConcept C159110408 @default.
- W4220966716 hasConcept C181199279 @default.
- W4220966716 hasConcept C184235292 @default.
- W4220966716 hasConcept C185592680 @default.
- W4220966716 hasConcept C190283241 @default.
- W4220966716 hasConcept C21951064 @default.
- W4220966716 hasConcept C2776330855 @default.
- W4220966716 hasConcept C2777366897 @default.
- W4220966716 hasConcept C2778918659 @default.
- W4220966716 hasConcept C2779321679 @default.
- W4220966716 hasConcept C2780601828 @default.
- W4220966716 hasConcept C29537977 @default.
- W4220966716 hasConcept C41625074 @default.
- W4220966716 hasConcept C41685203 @default.
- W4220966716 hasConcept C55493867 @default.
- W4220966716 hasConcept C71924100 @default.